β-catenin-IN-10
β-catenin-IN-10 is a β-catenin:TCF4 interaction inhibitor with an IC50 of 5.44 μM. β-catenin-IN-10 inhibits the Wnt and AR signaling pathways with IC50 values of 0.105 μM and 1.02 μM, respectively. β-catenin-IN-10 suppresses the proliferation of castration-resistant prostate cancer cells. β-catenin-IN-10 is applicable to research related to prostate cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C74H97N11O17
- 分子量:1412.63
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
体外実験
β-catenin-IN-10 (10 μM; 24 h) regulates the expression of Wnt and AR target genes in LNCaP-abl and LNCaP-95 prostate cancer cells, reduces oncogenic target transcripts, and upregulates E-cadherin[1].
β-catenin-IN-10 (0.195-0.782 μM; 5 d) potently inhibits the proliferation of castration-resistant prostate cancer cells LNCaP-abl and LNCaP-95 in 2D culture systems, with IC50 values of 0.195 μM and 0.782 μM for the two cell lines, respectively, but exerts no effect on non-prostate cancer cells independent of Wnt signaling[1].
β-catenin-IN-10 (0.694-1.34 μM; 17-22 d) inhibits the proliferation of LNCaP-abl prostate cancer spheroids in a 3D culture system; when the compound is added at the time of seeding, its IC50 is 0.694 μM, whereas when added to pre-formed spheroids, the IC50 is 1.34 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:LNCaP-abl and LNCaP-95 castration-resistant prostate cancer cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Decreased mRNA levels of Wnt target genes (AR, cMYC, Cyclin D1), AR target genes (PSA, FKBP5), and the constitutively active AR splice variant AR-V7; increased mRNA levels of E-cadherin, a gene repressed by Wnt signaling.
-
Cell Line:LNCaP-abl, LNCaP-95, U2OS, and A549 cells
-
Concentration:0.195 μM IC50 (LNCaP-abl); 0.782 μM IC50 (LNCaP-95); 0.001 to 100 μM (dose range)
-
Incubation Time:5 days
-
Result:Inhibited proliferation of LNCaP-abl cells with an IC50 of 0.195 μM and LNCaP-95 cells with an IC50 of 0.782 μM; had no effect on proliferation of Wnt-independent U2OS (osteosarcoma) and A549 (lung adenocarcinoma) cells.
-
Cell Line:LNCaP-abl prostate cancer cells
-
Concentration:0.694 μM IC50 (Day 0 addition); 1.34 μM IC50 (Day 5 addition); 0.001 to 100 μM (dose range); ≥1 μM (spheroid formation inhibition/growth stall)
-
Incubation Time:22 days total (Day 0 addition, media changes every 3-4 days); 17 days total (Day 5 addition, media changes every 3-4 days)
-
Result:When added on Day 0, inhibited spheroid proliferation with an IC50 of 0.694 μM; when added to pre-formed spheroids on Day 5, inhibited proliferation with an IC50 of 1.34 μM.
Concentrations ≥1 μM prevented spheroid formation or stalled growth of pre-formed spheroids.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:wild-type (embryos)[1]
-
Dosage:10 μM
-
Administration:immersion; single dose at 5.5 hours post-fertilization
-
Result:Rescued eye development in 100% of embryos (8/8 embryos in each of 3 independent experiments).
化学情報
-
分子量 1412.63
-
分子式 C74H97N11O17
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
β-catenin-IN-10 関連分類
HY-P11660 関連分類
Powered by Bioz